{"id":"fidaxomicin-tablets","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Nausea"},{"rate":"1-3","effect":"Vomiting"},{"rate":"2-4","effect":"Abdominal pain"},{"rate":"1-2","effect":"Diarrhea"},{"rate":"1-2","effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fidaxomicin binds to bacterial RNA polymerase and inhibits transcription in C. difficile, leading to bacterial cell death. Its narrow spectrum of activity and minimal systemic absorption make it particularly effective for treating C. difficile infection while preserving the beneficial microbiome, reducing recurrence rates compared to broader-spectrum antibiotics.","oneSentence":"Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, selectively killing Clostridioides difficile while minimizing effects on normal gut flora.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:44.567Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clostridioides difficile infection (CDI), including initial episode and recurrent infection"}]},"trialDetails":[{"nctId":"NCT02218372","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2015-01-09","conditions":"Clostridium Difficile-associated Diarrhea (CDAD)","enrollment":148},{"nctId":"NCT02437591","phase":"PHASE4","title":"Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2015-08-13","conditions":"Inflammatory Bowel Disease (IBD), Clostridium Difficile Infection (CDI)","enrollment":25},{"nctId":"NCT02254967","phase":"PHASE4","title":"A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2014-11-06","conditions":"Clostridium Difficile","enrollment":364},{"nctId":"NCT01591863","phase":"PHASE2","title":"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-06-15","conditions":"Clostridium Difficile-associated Diarrhea","enrollment":38},{"nctId":"NCT01691248","phase":"PHASE3","title":"Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-10-10","conditions":"Clostridium Difficile-Associated Diarrhea (CDAD)","enrollment":611},{"nctId":"NCT02784002","phase":"PHASE2","title":"A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)","status":"COMPLETED","sponsor":"Summit Therapeutics","startDate":"2014-12","conditions":"Clostridium Difficile Infection","enrollment":27}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"FULL BLOOD COUNT DECREASED"},{"count":1,"reaction":"THROMBOCYTOPENIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dificlir","Dificid"],"phase":"phase_3","status":"active","brandName":"Fidaxomicin tablets","genericName":"Fidaxomicin tablets","companyName":"Astellas Pharma Europe B.V.","companyId":"astellas-pharma-europe-b-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, selectively killing Clostridioides difficile while minimizing effects on normal gut flora. Used for Clostridioides difficile infection (CDI), including initial episode and recurrent infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}